Abstract
This paper describes the development and preliminary testing of a competitive surface-enhanced Raman scattering (SERS) immunoassay for calcitriol, the 1,25-dihydroxy metabolite (1,25-(OH)2-D3) of vitamin D3. Deficiencies in 1,25-(OH)2-D have been linked to renal disease, while elevations are linked to hypercalcemia. Thus, there has been a sharp increase in the clinical demand for measurements of this metabolite. The work herein extends the many attributes of SERS-based sandwich immunoassays that have been exploited extensively in the detection of large biolytes (e.g., DNA, proteins, viruses, and microorganisms) into a competitive immunoassay for the low level determination of a small biolyte, 1,25-(OH)2-D3 (Mw = 416 g mol-1). The assay uses surface modified gold nanoparticles as SERS labels, and has a dynamic range of 10-200 pg mL -1 and a limit of detection of 8.4 ± 1.8 pg mL-1. These analytical performance metrics match those of tests for 1,25-(OH) 2-D3 that rely on radio- or enzyme-labels, while using a much smaller sample volume and eliminating the disposal of radioactive wastes. Moreover, the SERS-based data from pooled-patient sera show strong agreement with that from radioimmunoassays. The merits and potential utility of this new assay are briefly discussed.
| Original language | English |
|---|---|
| Pages (from-to) | 2811-2817 |
| Number of pages | 7 |
| Journal | Analyst |
| Volume | 135 |
| Issue number | 11 |
| DOIs | |
| State | Published - Nov 2010 |
Fingerprint
Dive into the research topics of 'Competitive surface-enhanced Raman scattering assay for the 1,25-dihydroxy metabolite of vitamin D3'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver